This site contains promotional content intended for UK Healthcare Professionals and other relevant decision makers | Not a HCP? Visit our  Public Site.
Adverse Event reporting can be found at the bottom of the page | Prescribing Information for the relevant medicine can be found adjacent to the below content and/or in the footer below. 

Cardiovascular
Cardiovascular
Womens Health
Women's Health
two kidneys
Nephrology
Oncology
Oncology
Ophthalmology
Ophthalmology
Respiratory
Respiratory
Bayer for ProfessionalsYour Resource Portal
- EYLEA General -
- nAMD -
- DMO -
- RVO -
- mCNV -

RETINAL VEIN OCCLUSION (BRANCH RVO OR CENTRAL RVO)

Create a future you and your patients could look forward to with EYLEA 2 mg in RVO
1

EYLEA 2 mg is indicated for adults for the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO).1

 

Sudden vision loss due to RVO could have a profound long-term impact on patients’ lives. Choosing EYLEA 2 mg could benefit your RVO patients:

EYLEA 2 mg can deliver rapid and maintained vision gains from baseline in BRVO and CRVO2−8

 

  • Real-world evidence from Moorfields Eye Hospital complements CRVO RCTs9

With EYLEA 2 mg, your RVO patients could look forward to rapid and maintained vision gains from baseline
2–8

Click to see how RCT outcomes support the early use of EYLEA 2 mg in your RVO patients:

EYLEA 2 mg was associated with rapid vision gains from baseline, maintained to Week 52 in BRVO2,3

View Details

VIBRANT

BRVO patients on EYLEA 2 mg saw rapid vision gains from baseline, maintained to Week 52.2,3

≥15-LETTER VISION GAINS

Adapted from Campochiaro PA, et al. 2015 & Clark WL, et al. 2016.

GALILEO and COPERNICUS

Early treatment with EYLEA 2 mg was associated with rapid and maintained vision gains from baseline in CRVO.4,5

 

GALILEO

GALILEO-≥15-LETTER VISION GAINS

Adapted from Ogura Y, et al. 2014.

No direct cross-trial comparisons can be made between GALILEO and COPERNICUS due to differing study designs.

COPERNICUS

COPERNICUS - ≥15-LETTER VISION GAINS

Adapted from Heier JS, et al. 2014.

No direct cross-trial comparisons can be made between GALILEO and COPERNICUS due to differing study designs.

In COPERNICUS and GALILEO, CRVO patients treated within 2 months of diagnosis gained 20.2 letters from baseline at 6 months, vs. 13.4 letters for patients treated later¹⁵

CENTERA

CENTERA shows CRVO patients can achieve clinically meaningful vision gains vs. baseline on a T&E regimen.6*

CENTERA-≥15-LETTER VISION GAINS

Adapted from Korobelnik J-F, et al. 2021.

*Following 4 x weekly injections until disease stability or until Week 20, whichever occurred first.

In CENTERA, CRVO patients achieved rapid vision gains from baseline, maintained to Week 76 with EYLEA 2 mg T&E dosing.6*

CENTERA-≥15-LETTER VISION GAINS

Adapted from Korobelnik J-F, et al. 2021.

*Following 4 x weekly injections until disease stability or until Week 20, whichever occurred first.

Vision gains from baseline in CRVO patients on EYLEA 2 mg can be maintained in the long term with T&E dosing⁶

LEAVO

EYLEA 2 mg delivered rapid and maintained vision gains from baseline, with significantly fewer injections vs. ranibizumab in CRVO.7,8

LEAVO-≥15-LETTER VISION GAINS

Adapted from Hykin P, et al. 2019.

No significant difference in BCVA letters gained between treatment groups at Week 52: treatment difference 0.7% (95% CI: -11.0, 12.5)

SAFETY PROFILE IN RCTS

The safety profile of EYLEA 2 mg was evaluated in clinical trials for up to 52 weeks (VIBRANT), 76 weeks (GALILEO and CENTERA) and 100 weeks (COPERNICUS and LEAVO)2−7,17

 

EYLEA 2 mg was well tolerated across studies, with the most common AEs typically associated with intravitreal injections or the underlying disease3−6,17

INJECTION NUMBERS

In LEAVO and Casselholm de Salles, et al, EYLEA 2 mg could deliver non-inferior vision gains from baseline with fewer injections vs. ranibizumab in CRVO.7,10

INJECTION NUMBERS-LEAVO

*Statistically significant difference in mean number of injections between EYLEA 2 mg and ranibizumab at all three timepoints assessed: Week 24 (mean difference: -0.4, 95% CI:-0.6, -0.2); Week 52 (-1.1; 95% CI: -1.6, -0.5): Week 100 (-1.9, 95% CI: -2.9, -0.8).7

Patients on EYLEA 2 mg had significantly fewer injections vs. ranibizumab,⁷𝄒¹⁰ which may help to improve clinic capacity.

Real-world evidence

Look forward to real-world results – EYLEA 2 mg delivers RCT-like outcomes for your RVO patients in clinical practice.9

Real-world evidence from Moorfields Eye Hospital complements RCT results in CRVO.9

  • Vision gains achieved vs. baseline with EYLEA 2 mg were maintained using a treat-and-extend regimen after 3 initial monthly doses in patients with CRVO (n=33)9

Mean vision gains from baseline
9

REAL-WORLD EVIDENCE-VISION GAIN OVER TIME

Adapted from Eleftheriadou M, et al. 2019.

Look forward to real-world results – EYLEA 2 mg delivers RCT-like outcomes for your RVO patients in clinical practice⁹
Dosing

Full details of proactive dosing in BRVO and CRVO1

MoA

Innovative molecular design and mechanism of action1,18–22

Safety

Established safety profile in RVO1

Abbreviations

2Q4, 2 mg every 4 weeks. AE, adverse event. BCVA, best-corrected visual acuity. BRVO, branch retinal vein occlusion. CI, confidence interval. CRVO, central retinal vein occlusion. CRT, central retinal thickness. CST, central subfield thickness. DMO, diabetic macular oedema. ETDRS, Early Treatment Diabetic Retinopathy Study. HRVO, hemi-retinal vein occlusion. IQR, interquartile range. IVT, intravitreal. MoA, mechanism of action. nAMD, neovascular age-related macular degeneration. NICE, National Institute for Health and Care Excellence. OCT, optical coherence tomography. PRN, pro re nata (as needed). Q12, every 12 weeks. RCT, randomised controlled trial. RVO, retinal vein occlusion. SD, standard deviation. T&E, treat and extend. VA, visual acuity.

References

  1. EYLEA® 40 mg/mL Summary of Product Characteristics.
  2. Campochiaro PA, et al. Ophthalmology 2015;122:538–544.
  3. Clark WL, et al. JAMA Ophthalmology 2016;123:330–336.
  4. Heier JS, et al. Ophthalmology 2014;121:1414–1420.e1.
  5. Ogura Y, et al. Am J Ophthalmol 2014;158:1032–1038.
  6. Korobelnik J-F, et al. Am J Ophthalmol 2021;227:106–115.
  7. Hykin P, et al. JAMA Ophthalmol 2019;137:1256–1264.
  8. Hykin P, et al. Presentation at the Association for Research in Vision and Ophthalmology (ARVO). 28 April – 2 May 2019. Vancouver, Canada.
  9. Eleftheriadou M, et al. Ophthalmol Ther 2019;8:289–296.
  10. Casselholm de Salles M, et al. Retina 2019;39:1370–1376.
  11. NICE. Technology appraisal guidance [TA409]. 2016. Available at: https://www.nice.org.uk/Guidance/TA409. Accessed: September 2024.
  12. Korobelnik J-F, et al. Ophthalmology 2014;121:202–208.
  13. Holz FG, et al. Br J Ophthalmol 2013;97:278–284.
  14. Brown DM, et al. Am J Ophthalmol 2013;155:429–437.e7.
  15. Boyer D, et al. Ophthalmology 2012;119:1024–1032.
  16. Avastin® Summary of Product Characteristics.
  17. Bayer. Data on File. EYLB019.
  18. Fauser S & Muether PS. Br J Ophthalmol 2016;100:1494–1498.
  19. EMA. EYLEA EPAR assessment report 2012. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/eylea. Accessed: September 2024.
  20. Papadopoulos N, et al. Angiogenesis 2012;15:171–185.
  21. Kanda A, et al. Sci Rep 2015;5:17946.
  22. Amadio M, et al. Pharmacol Res 2016;103:253–269.

PP-EYL-GB-2333 | September 2024

Next Page
RVO Dosing